Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ARX305 is the only anti-CD70 ADC in active development that targets CD70, a protein that is overexpressed in a broad range of solid and hematologic tumors, giving it the potential to treat a range of liquid and solid tumor cancers, where CD70 is overexpressed.
Lead Product(s): ARX305
Therapeutic Area: Oncology Product Name: ARX305
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Ambrx Inc
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Agreement November 09, 2022